Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-week randomized double-blind study of umeclidinium + vilanterol versus umeclidinium versus salmeterol in COPD
2016-002513-22Phase 4Completed
- Sponsor
- GSK
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Umeclidinium + vilanterol, Umeclidinium and Salmeterol (3 arms). Primary endpoint: Change from baseline in trough Forced Expiratory Volume in One Second (FEV1) at week 24. Started Dec 2016; status: completed.
02
Drugs
vilanterolumeclidiniumsalmeterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2016-002513-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002513-22.